<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088123</url>
  </required_header>
  <id_info>
    <org_study_id>NCR191544</org_study_id>
    <secondary_id>U54MD010723</secondary_id>
    <secondary_id>Pharmacy Faculty Fund</secondary_id>
    <secondary_id>PIND 144269</secondary_id>
    <nct_id>NCT04088123</nct_id>
  </id_info>
  <brief_title>Impact of Anti-platelet Drug Exposure on Platelet mRNA Splicing in Healthy Subjects</brief_title>
  <official_title>Investigation of Anti-platelet Drug Single Dose Exposure on Platelet mRNA Splicing in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenandoah University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The GW Medical Faculty Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine how the anti-platelet drug, ticagrelor,
      impacts platelet mRNA splicing after a single loading dose in 10 healthy participants. These
      results will be valuable in that they will help inform our analysis of platelet RNA splicing
      after a thrombotic event.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is nothing known on how differential splicing in platelets is impacted by of P2Y12
      inhibition by anti-platelet agents. Consequently, the focus of this longitudinal pilot study
      will be to determine the impact of a single ticagrelor loading dose (180 mg), our &quot;model&quot;
      anti-platelet drug, on platelet RNA splicing in 10 healthy individuals.

      It will test the hypothesis that ticagrelor exposure does not significantly alter platelet
      mRNA splicing. It will involve administering a single loading dose (180 mg) of ticagrelor to
      healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the Change in Platelet Activity From Baseline after Drug Administration</measure>
    <time_frame>Comparison made 2.5 hours following drug administration</time_frame>
    <description>As determined by the VerifyNow P2Y12 Assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the Change in Platelet mRNA splicing From Baseline after Drug Administration</measure>
    <time_frame>Comparison made 2.5 hours following drug administration</time_frame>
    <description>As determined by RNAseq analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Ticagrelor Pharmacokinetics After Drug Administration</measure>
    <time_frame>Comparison made 2.5 hours following drug administration</time_frame>
    <description>Drug and its major metabolite levels will be measured by HPLC</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Thrombosis; Artery</condition>
  <arm_group>
    <arm_group_label>Healthy Patients</arm_group_label>
    <description>The study design will involve analysis of platelet splicing/activity before and after exposure to a single, 180 mg loading dose of ticagrelor. All subjects will be cardiovascular healthy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor Oral Tablet [Brilinta]</intervention_name>
    <description>A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.</description>
    <arm_group_label>Healthy Patients</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The following materials will be obtained from each participant. Blood for RNA (RNAseq) and
      DNA (genotyping) and platelet activity analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy patients who meet our inclusion and exclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 70 years-old

          -  Speak and understand English

        Exclusion Criteria:

          -  History of blood clotting/bleeding disorders

          -  Current medications that are CYP3A4 inhibitors/inducers

          -  Current medications that their pharmacokinetics is impacted by ticagrelor (i.e.
             simvastatin, lovastatin, digoxin) per FDA recommendations.

          -  Diagnosed with arterial or venous thrombosis

          -  Active cancer diagnosis

          -  Pregnant

          -  Hepatic impairment including active hepatitis infection or cirrhosis

          -  Current hormonal contraception

          -  Currently taking aspirin or anti-platelet drugs. If patient has recently taken an
             NSAID, the last dose should have been discontinued based established criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Travis J O'Brien, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Travis J O'Brien, PHD</last_name>
    <phone>2029943373</phone>
    <email>phmtjo@gwu.ed</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Barbour, MD</last_name>
    <phone>2027412222</phone>
    <email>abarbour@mfa.gwu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The George Washington University School of Medicine and Health Sciences</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Travis J O'Brien, PhD</last_name>
      <phone>202-994-3373</phone>
      <email>phmtjo@gwu.edu</email>
    </contact>
    <contact_backup>
      <last_name>April Barbour, MD</last_name>
      <phone>2027412222</phone>
      <email>abarbour@mfa.gwu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Norman Lee, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenandoah University Bernard J. Dunn School of Pharmacy</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Arthur Harralson, PharmD</last_name>
      <phone>571-472-2400</phone>
      <email>aharrals@su.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Travis J. O'Brien</investigator_full_name>
    <investigator_title>Associate Professor of Pharmacology and Physiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared with researchers. Only aggregate data from the study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

